August 9, 2011 was a day to remember for college student Li Mou, on which Professor Gao Changqing, a renowned cardiac surgeon in China, successfully performed a left ventricular outflow tract evacuation (also known as modified MORROW surgery) on this young man who had been suffering from cardiomyopathy for more than 10 years. 10 years ago, Li Mou should have been a lively and active teenager, but he was already haunted by a relentless heart disease that prevented him from walking fast and caused shortness of breath when he was active. In 2007, he underwent an interventional alcohol chemical ablation procedure, but his symptoms did not improve. Despite the disease, the bright and diligent young man did not give up the pursuit of life, and successfully passed the college entrance examination in 2008 to become a university student, but the pressure of study and the progress of the disease made Li’s condition worsen day by day, and when serious, he could not lie down to rest. Ultrasound examination indicated that the cardiac function was significantly reduced, and the left ventricular ejection fraction (EF), an indicator of cardiac function, was only 31%. A specialist hospital in China had recommended heart transplantation, and the young man who could not hold on to his studies came to the PLA General Hospital with his family to find Professor Gao Changqing with a ray of hope. After careful preoperative examination and preparation, Professor Gao performed the left ventricular outflow tract evacuation for the handsome college boy, removing the hypertrophic septal muscle that was causing the blockage of heart ejection and completely evacuating the left ventricular outflow tract, and intraoperative ultrasound examination of the esophagus showed that the left ventricular outflow tract pressure differential was significantly reduced from 82 mmHg to 5 mmHg before surgery. The postoperative cardiac ultrasound showed normal cardiac function. The operation was successful, and a stone fell from the hearts of Li’s parents, the young man’s frowning brow was stretched, and his handsome face showed a happy smile, and he was discharged from the hospital 2 weeks after the operation. The young man did not forget his life-saving benefactor after his discharge, and wrote a letter a month later to thank Professor Gao Changqing who operated on him. The day of the school year has arrived, the young man who has cured his heart disease will return to his eager university campus …… Hypertrophic cardiomyopathy is a common heart disease, China’s epidemiological survey shows that the prevalence of hypertrophic cardiomyopathy in the Chinese population is 0.8 per thousand, there are about 1 million patients. Hypertrophic obstructive cardiomyopathy is a subtype of hypertrophic cardiomyopathy other than the nonobstructive type (20% of cases), also known as idiopathic hypertrophic subaortic stenosis. The main pathological change is left ventricular outflow tract obstruction due to asymmetric hypertrophy of the ventricular septum and left ventricular free wall, which leads to a significantly increased risk of progressive heart failure, stroke, and sudden death. The disease is usually diagnosed with symptoms of exertional dyspnea, angina pectoris, a history of syncope, and a family history of sudden death, and is most often diagnosed with cardiac ultrasonography. For the treatment of hypertrophic obstructive cardiomyopathy, drugs are the first choice, and surgery is required for those who do not respond to drug therapy. The surgical treatment of hypertrophic obstructive cardiomyopathy began in the late 1950s, and Morrow et al. reported the surgical treatment in 1968, which has become the classic surgical method and is still used today. Studies have shown that the long-term survival rate of surgical patients is comparable to that of the general population and significantly better than that of those who have not undergone surgery. Although the development of new interventional methods such as dual-chamber pacemakers and septal alcohol ablation has provided more clinical options in recent years, their effectiveness still cannot replace surgical treatment. The expert consensus is that surgical treatment is still the “gold standard” for the treatment of hypertrophic obstructive cardiomyopathy. However, due to the high risk of surgery, some of the unsatisfactory results and high perioperative complications, the use of such surgery is less popular in China. In the past 10 years, the cardiovascular surgery department of PLA General Hospital under the leadership of Director Gao Changqing has treated nearly 100 patients with satisfactory results, with no early surgical deaths, no serious complications such as septal perforation and high atrioventricular block. The results of cardiac ultrasound examination showed that the postoperative septal thickness (11.8±3.2 mm) was significantly thinner than that before surgery (28.3±7.9 mm), and the left ventricular outflow tract pressure difference (17.9±12.9 mmHg) was significantly lower than that before surgery (89.3±31.1 mmHg). Postoperative follow-up patients all had significant reduction or disappearance of preoperative symptoms and returned to normal life. The studies related to this type of surgery have been reported in international and domestic professional academic conferences and have received unanimous affirmation and praise.